- Home
- NDLS vs SCYX Comparison
NDLS vs SCYX Comparison
Compare NDLS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- SCYX
- Stock Information
- Founded
- NDLS 1995
- SCYX 1999
- Country
- NDLS United States
- SCYX United States
- Employees
- NDLS N/A
- SCYX N/A
- Industry
- NDLS Restaurants
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- SCYX Health Care
- Exchange
- NDLS Nasdaq
- SCYX Nasdaq
- Market Cap
- NDLS 32.9M
- SCYX 28.5M
- IPO Year
- NDLS 2013
- SCYX 2014
- Fundamental
- Price
- NDLS $0.80
- SCYX $0.71
- Analyst Decision
- NDLS Strong Buy
- SCYX
- Analyst Count
- NDLS 2
- SCYX 0
- Target Price
- NDLS $3.00
- SCYX N/A
- AVG Volume (30 Days)
- NDLS 212.2K
- SCYX 115.9K
- Earning Date
- NDLS 08-06-2025
- SCYX 08-07-2025
- Dividend Yield
- NDLS N/A
- SCYX N/A
- EPS Growth
- NDLS N/A
- SCYX N/A
- EPS
- NDLS N/A
- SCYX N/A
- Revenue
- NDLS $495,670,000.00
- SCYX $2,630,000.00
- Revenue This Year
- NDLS $5.37
- SCYX $463.61
- Revenue Next Year
- NDLS $0.68
- SCYX $310.80
- P/E Ratio
- NDLS N/A
- SCYX N/A
- Revenue Growth
- NDLS N/A
- SCYX N/A
- 52 Week Low
- NDLS $0.55
- SCYX $0.66
- 52 Week High
- NDLS $1.83
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- NDLS 52.86
- SCYX 39.58
- Support Level
- NDLS $0.66
- SCYX $0.70
- Resistance Level
- NDLS $0.82
- SCYX $0.75
- Average True Range (ATR)
- NDLS 0.07
- SCYX 0.05
- MACD
- NDLS 0.01
- SCYX 0.00
- Stochastic Oscillator
- NDLS 87.67
- SCYX 28.80
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.